Literature DB >> 21338040

Emerging oral therapies for multiple sclerosis.

Colleen E Miller1, Margaret A Umhauer.   

Abstract

Despite notable advances in the understanding of multiple sclerosis (MS) and the availability of several treatment options, there is a need for therapies that are more effective, safe, convenient, and well tolerated. Several new oral MS therapies are being investigated. Because data on these new therapies continue to emerge, nurses will play a pivotal role in educating patients regarding the benefits and risks of potential treatments and in monitoring patients for response, safety, tolerability, and adherence. This article reviews the oral MS therapies recently approved as well as those currently in development or submitted for Food and Drug Administration approval.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338040     DOI: 10.1097/jnn.0b013e31820297a9

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  1 in total

1.  Relapsing-remitting multiple sclerosis patients' experience with natalizumab: a phenomenological investigation.

Authors:  Colleen E Miller; Mary Karpinski; Mary Ann Jezewski
Journal:  Int J MS Care       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.